Skip to main content
Clinical Trials/NCT05530109
NCT05530109
Terminated
Not Applicable

Study of Attentional Disorders in Patients Suffering From Idiopathic Generalized Epilepsy.

University Hospital, Lille1 site in 1 country33 target enrollmentApril 26, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Idiopathic Generalized Epilepsy
Sponsor
University Hospital, Lille
Enrollment
33
Locations
1
Primary Endpoint
Epitrack scale score
Status
Terminated
Last Updated
11 months ago

Overview

Brief Summary

Attentional disorders have been reported in neuropsychological studies evaluating patients suffering from generalized idiopathic epilepsy, but the data are disparate (in terms of test protocol). We aim to describe attentional and executive function disorder in IGE thanks to the Epitrack scale, validated in this specific population. Our secondary objective is to study the dynamic of cortical activity during an attentional task (the ANT), in order to describe the alteration of cortical networks in epileptic patients presenting with attentional disturbance.

Registry
clinicaltrials.gov
Start Date
April 26, 2022
End Date
April 25, 2025
Last Updated
11 months ago
Study Type
Observational
Sex
All

Investigators

Sponsor
University Hospital, Lille
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Idiopathic generalized epilepsy followed-up during at least 2 years
  • At least one antiepileptic drug medication
  • No cognitive decline (MoCA score \>26)
  • Absence of concomitant pathology that could interfere with the purpose of the study.
  • Be affiliated to the social security system
  • Have signed an informed consent

Exclusion Criteria

  • Pregnancy
  • Not able to give consent (Article 1121-8 of the CSP) Vulnerable person Being deprived of liberty by judicial or administrative decision (Article L 1121-6 of the CSP) Have a high probability of not respecting the protocol or of abandoning the study

Outcomes

Primary Outcomes

Epitrack scale score

Time Frame: At 1 month after inclusion

EPITrack-Score shows the performance of attention and executive functions. Higher values indicate a better performance. scale from 9-49 (9 worst score - 49 best score)

Secondary Outcomes

  • D2-R test score(At 1 month after inclusion)
  • STAI scale(At 1 month after inclusion)
  • Raven's progressive matrice scores(At 1 month after inclusion)
  • Montreal Cognitive Assessment (MoCA) score(At 1 month after inclusion)
  • quality of life using the Qolie-31 self questionnaire(At 1 month after inclusion)
  • BDI-II score(At 1 month after inclusion)
  • High resolution Electro Encephalo Gram functional connectivity markers at rest and during the ANT task(At 1 month after inclusion)

Study Sites (1)

Loading locations...

Similar Trials